All In Biotech

Drug Trial Radar · NCT04315298

Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19

An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID-19

Last checked: Nov 20, 2026Latest source record: Sep 23, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,912 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,912

Actual

Start

Mar 18, 2020

Primary completion

Jul 24, 2020

Study completion Sep 2, 2020

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
Collaborators
Sanofi
First posted
Mar 19, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 2: The primary objective of the study is to evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with COVID-19 regardless of disease severity strata. Phase 3 Cohort 1: The primary objective of the study is to evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with critical COVID-19 receiving mechanical ventilation at baseline. Phase 3 Cohort 2: The primary objective of the study is to evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with COVID-19 receiving mechanical ventilation at baseline.

Conditions

  • COVID-19

Interventions

  • SarilumabDrug

    Single or multiple intravenous (IV) doses of sarilumab. Additional doses may be administered if the patient meets protocol defined criteria.

  • PlaceboDrug

    Single or multiple intravenous (IV) doses of placebo to match sarilumab administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline in CRP Levels at Day 4 in Participants With Serum IL-6 Level Greater Than the ULN (Phase 2)Time frame: Baseline and Day 4
  2. Percentage of Participants With at Least a 1-point Improvement in Clinical Status From Baseline to Day 22 Using the 7-point Ordinal Scale in Participants With Critical COVID-19 Receiving Mechanical Ventilation at Baseline (Phase 3 Cohort 1)Time frame: Day 22
  3. Percentage of Participants With at Least 1-point Improvement in Clinical Status Using the 7-point Ordinal Scale in Participants With COVID-19 Receiving Mechanical Ventilation at Baseline (Phase 3 Cohort 2)Time frame: Day 22

Locations

62 sites in 1 country. Site status is shown where the registry gives one.

  • Regeneron Study Site

    Los Angeles, California

  • Regeneron Study Site

    Sacramento, California

  • Regeneron Study Site

    Santa Monica, California

  • Regeneron Study Site

    Aurora, Colorado

  • Regeneron Study Site

    Denver, Colorado

  • Regeneron Study Site

    New Haven, Connecticut

  • Regeneron Study Site

    Washington D.C., District of Columbia

  • Regeneron Study Site

    Gainesville, Florida

  • Regeneron Study Site

    Orlando, Florida

  • Regeneron Study Site

    Tampa, Florida

  • Regeneron Study Site

    Atlanta, Georgia

  • Regeneron Study Site

    Decatur, Georgia

  • Regeneron Study Site

    Marietta, Georgia

  • Regeneron Study Site

    Chicago, Illinois

  • Regeneron Study Site

    Chicago, Illinois

  • Regeneron Study Site

    New Orleans, Louisiana

  • Regeneron Study Site

    Boston, Massachusetts

  • Regeneron Study Site

    Boston, Massachusetts

  • Regeneron Study Site

    Boston, Massachusetts

  • Regeneron Study Site

    Ann Arbor, Michigan

  • Regeneron Study Site

    Rochester, Minnesota

  • Regeneron Study Site

    Edison, New Jersey

  • Regeneron Study Site

    Hackensack, New Jersey

  • Regeneron Study Site

    Livingston, New Jersey

  • Regeneron Study Site

    Morristown, New Jersey

  • Regeneron Study Site

    Neptune City, New Jersey

  • Regeneron Study Site

    Newark, New Jersey

  • Regeneron Study Site

    Teaneck, New Jersey

  • Regeneron Study Site

    Brooklyn, New York

  • Regeneron Study Site

    Buffalo, New York

  • Regeneron Study Site

    Elmhurst, New York

  • Regeneron Study Site 1

    Manhasset, New York

  • Regeneron Study Site 2

    Manhasset, New York

  • Regeneron Study Site

    New York, New York

  • Regeneron Study Site

    New York, New York

  • Regeneron Study Site 1

    New York, New York

  • Regeneron Study Site 2

    New York, New York

  • Regeneron Study Site

    New York, New York

  • Regeneron Study Site

    New York, New York

  • Regeneron Study Site

    New York, New York

Showing 40 of 62 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.